Genetic Testing Market Report 2026

The genetic testing market size has grown strongly in recent years. It will grow from $20.84 billion in 2025 to $22.91 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to advancements in molecular biology, declining dna sequencing costs, increased awareness of genetic disorders, expansion of diagnostic laboratories, early adoption in oncology.

The genetic testing market size is expected to see strong growth in the next few years. It will grow to $32.22 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growth of personalized medicine, integration of genetic data in clinical decisions, rising chronic disease burden, expansion of preventive healthcare, improved genetic counseling services. Major trends in the forecast period include increasing adoption of predictive genetic testing, growing use of prenatal and newborn screening, rising demand for pharmacogenomics testing, expansion of cancer genetic diagnostics, increased availability of direct-to-consumer genetic tests.

The increasing prevalence of genetic disorders is anticipated to drive the growth of the genetic testing market in the coming years. Genetic disorders include conditions that may be present at birth as well as those that develop later in life. Genetic testing plays a crucial role in diagnosing genetic conditions and providing insights into an individual’s risk of developing diseases such as cancer. For example, in 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, genetic disorders and congenital anomalies affect around 2%-5% of live births and account for approximately 30% of pediatric hospital admissions, contributing to nearly 50% of childhood deaths in industrialized nations. As a result, the growing burden of genetic disorders is fueling demand for genetic testing services.

Leading companies in the genetic testing market are increasingly focusing on innovative solutions, including AI-driven genomic interpretation algorithms, to address the rising need for improved variant classification, higher diagnostic accuracy, and broader adoption of precision healthcare. AI-based genomic interpretation tools process large-scale genetic data to identify disease-causing variants more efficiently than conventional manual or rule-based approaches, enabling faster insights, reduced uncertainty, and improved predictive accuracy. For instance, in June 2023, Illumina, Inc., a US-based biotechnology and medical equipment company, introduced PrimateAI-3D, an advanced artificial intelligence algorithm developed to predict pathogenic genetic mutations. The tool leverages three-dimensional protein structural analysis and evolutionary comparisons across primate species to prioritize potentially harmful variants. By enhancing large-scale genomic interpretation, it accelerates precision medicine initiatives and improves diagnostic workflows, allowing researchers and clinicians to assess genetic risks more accurately. PrimateAI-3D supports quicker and more dependable identification of clinically relevant mutations, thereby strengthening overall genetic testing capabilities.

In February 2025, Tempus, a US-based company specializing in precision medicine solutions, AI-powered clinical insights, and oncology-focused genetic testing services, completed the acquisition of Ambry Genetics for an undisclosed sum. Through this acquisition, Tempus seeks to broaden its genetic testing offerings and incorporate Ambry’s hereditary disease testing expertise into its precision medicine platform, thereby enhancing its technological strengths and expanding its presence in the clinical genetic diagnostics market. Ambry Genetics is a US-based provider of genetic testing services for hereditary cancer, cardiovascular conditions, pediatric disorders, and rare diseases.

Major companies operating in the genetic testing market are Myriad Genetics Inc, Illumina Inc, Abbott Laboratories, Eurofins Scientific, Danaher Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Qiagen NV, Thermo Fisher Scientific Inc., BioRad Laboratories Inc., BGI, Berry Genomics Co. Ltd, Daan Gene Co. Ltd, Annoroad Gene Technology Co. Ltd, Igenomix, Circle DNA, Centogene, Probably Genetic, Genome Biologics, WuXi NextCODE, Genomtec, Testgene, Evogen Lab, Phosphorus, Helix, 10x Genomics, Quantgene, DNALabs, Deep Genomics, Hologic Inc, Molecular Biology & Genetics Laboratory, IVI MIDDLE EAST FERTILITY CLINIC, Bio Certica.

North America was the largest region in the genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genetic testing market by increasing costs of imported reagents, testing kits, sequencing instruments, and laboratory consumables. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported technologies, while Asia-Pacific faces higher setup costs for advanced testing infrastructure. These tariffs raise testing prices but encourage local manufacturing of reagents and diagnostic equipment.

The genetic testing market research report is one of a series of new reports that provides genetic testing market statistics, including genetic testing industry global market size, regional shares, competitors with a genetic testing market share, detailed genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the genetic testing industry. This genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genetic testing is a type of medical assessment that examines changes in genes, proteins, or chromosomes. The outcomes of a genetic test can help identify a genetic condition or assess an individual’s likelihood of developing a genetic disorder. Genetic testing is commonly used to confirm specific inherited conditions in children by evaluating their physical signs and symptoms.

The primary types of genetic testing include predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, nutrigenomic testing, and other related tests. Predictive testing represents a newer and rapidly growing category of medical tests that differs significantly from conventional diagnostic procedures. The key technologies used in genetic testing include cytogenetic testing, biochemical testing, and molecular testing. These tests are applied across multiple areas, such as cancer diagnosis, genetic disease identification, cardiovascular disease assessment, and others, and are utilized by various end users including hospitals and clinics, diagnostic laboratories and centers, and other healthcare settings.

The genetic testing market includes revenues earned by entities by chromosomal genetic tests, molecular genetic tests (or gene tests), biochemical tests, newborn screening, and diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.